Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Pfizer (PFE) Tops Q4 EPS by 28c, Tops on Revenue; Offers Guidance
January 30, 2024 6:46 AM ESTPfizer (NYSE: PFE) reported Q4 EPS of $0.10, $0.28 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $14.25 billion versus the consensus estimate of $14.22 billion.
The company reaffirms Full-Year 2024 guidance provided on December 13, 2023, of Revenues of $58.5 to $61.5 Billion and Adjusted... More
